These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32655465)

  • 1. Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias.
    Modoni A; D'Amico A; Primiano G; Capozzoli F; Desaphy JF; Lo Monaco M
    Front Neurol; 2020; 11():300. PubMed ID: 32655465
    [No Abstract]   [Full Text] [Related]  

  • 2. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
    Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J
    Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.
    Lo Monaco M; D'Amico A; Luigetti M; Desaphy JF; Modoni A
    Clin Neurophysiol; 2015 Feb; 126(2):399-403. PubMed ID: 25065301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
    Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B
    Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.
    Chapman AM; Schurer M; Weijers L; Omar A; Lee H; Weidenfeller AZ; Ellis C; Sonecha S; Schneider-Gold C
    BMC Neurol; 2021 Dec; 21(1):467. PubMed ID: 34852780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-rate repetitive nerve stimulation protocol in an Italian cohort of patients affected by recessive myotonia congenita.
    Modoni A; D'Amico A; Dallapiccola B; Mereu ML; Merlini L; Pagliarani S; Pisaneschi E; Silvestri G; Torrente I; Valente EM; Lo Monaco M
    J Clin Neurophysiol; 2011 Feb; 28(1):39-44. PubMed ID: 21221019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia.
    D'Mello S; Shum L
    Eur J Hosp Pharm; 2016 Nov; 23(6):359-363. PubMed ID: 31156883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond the muscular involvement in non-dystrophic myotonias: The emerging role of neuromodulation.
    Portaro S; Naro A; Bramanti A; Leo A; Manuli A; Balletta T; Trinchera A; Bramanti P; Calabrò RS
    Restor Neurol Neurosci; 2018; 36(4):459-467. PubMed ID: 29889082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.
    Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ
    BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
    Trump D
    Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine].
    Pouget J; Serratrice G
    Rev Neurol (Paris); 1983; 139(11):665-72. PubMed ID: 6677978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita.
    Ginanneschi F; Mignarri A; Lucchiari S; Ulzi G; Comi GP; Rossi A; Dotti MT
    Neurophysiol Clin; 2017 Jun; 47(3):247-252. PubMed ID: 28153715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2.
    Mousele C; Matthews E; Pitceathly RDS; Hanna MG; MacDonald S; Savvatis K; Carr A; Turner C
    Neurol Clin Pract; 2021 Oct; 11(5):e682-e685. PubMed ID: 34840883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: An Emerging Role of Endometrial Inflammasome in Reproduction: New Therapeutic Approaches.
    Fiorella Di Nicuolo, Monia Specchia, Lorenza Trentavizi, Alfredo Pontecorvi, Giovanni Scambiac and Nicoletta Di Simone
    Protein Pept Lett; 2019; 26(3):235. PubMed ID: 30942143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of Pregnancy on Different Genetic Subtypes of Non-Dystrophic Myotonia and Periodic Paralysis.
    Rudnik-Schöneborn S; Witsch-Baumgartner M; Zerres K
    Gynecol Obstet Invest; 2016; 81(5):472-6. PubMed ID: 27300293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myotonia congenita and myotonic dystrophy in the same family: coexistence of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene.
    Sun C; Van Ghelue M; Tranebjærg L; Thyssen F; Nilssen Ø; Torbergsen T
    Clin Genet; 2011 Dec; 80(6):574-80. PubMed ID: 21204798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of non-dystrophic myotonia with concomitant mutations in the SCN4A and CLCN1 genes.
    Kato H; Kokunai Y; Dalle C; Kubota T; Madokoro Y; Yuasa H; Uchida Y; Ikeda T; Mochizuki H; Nicole S; Fontaine B; Takahashi MP; Mitake S
    J Neurol Sci; 2016 Oct; 369():254-258. PubMed ID: 27653901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myotonia fluctuans. A third type of muscle sodium channel disease.
    Ricker K; Moxley RT; Heine R; Lehmann-Horn F
    Arch Neurol; 1994 Nov; 51(11):1095-102. PubMed ID: 7980103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium channel slow inactivation as a therapeutic target for myotonia congenita.
    Novak KR; Norman J; Mitchell JR; Pinter MJ; Rich MM
    Ann Neurol; 2015 Feb; 77(2):320-32. PubMed ID: 25515836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist.
    Hammarén E; Kjellby-Wendt G; Lindberg C
    Neuromuscul Disord; 2005 Oct; 15(9-10):610-7. PubMed ID: 16084086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.